This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Immunomedics Discovers Potential New Therapy For Graft-Versus-Host Disease

Stocks in this article: IMMU

MORRIS PLAINS, N.J., Oct. 9, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced the publication of a preclinical study that shows milatuzumab, the Company's proprietary humanized anti-CD74 antibody, effectively prevents the onset and manifestations of acute graft-versus-host disease (GVHD) in a humanized-mouse model.

Acute GVHD is a medical complication following bone marrow or stem cell transplant. It occurs when white blood cells transplanted from a donor start attacking the recipient's body after recognizing the recipient's body as foreign. According to published reports, the number of stem cell transplantations continues to increase, with more than 20,000 transplantations from donors performed annually worldwide. In 2006, the estimated number of stem cell transplantations reported in the U.S. to the Center for International Blood and Marrow Transplant Research was 6,100 (3,800 related donors and 2,300 unrelated donors).

The global incidence of acute GVHD ranges from 26% to 34% in recipients of full matched sibling donor grafts, to 42% to 52% in recipients of matched unrelated donor grafts, and is a major cause of non-relapse mortality, with >50% 2-year non-relapse mortality in patients with grade III/IV GVHD. Current therapy for acute GVHD is suboptimal, especially for patients who do not respond to corticosteroids, with an estimated 2 year non-relapse mortality of 73% in refractory patients. Prevention and treatment of GVHD remains a major challenge.

Milatuzumab is the first humanized anti-CD74 antibody currently being developed for the treatment of relapsed or refractory B-cell malignancies. Previous preclinical studies have shown that it has potent cytotoxicity against CD74-expressing malignant B cells. In addition to B cells, CD74 is also widely expressed in antigen-presenting cells (APCs), which include monocytes, macrophages, and dendritic cells (DCs). More recent preclinical studies have demonstrated that milatuzumab was capable of modulating human B-cell proliferation, migration, and adhesion molecule expression, suggesting that this antibody also may be effective in the therapy of autoimmune diseases.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs